Phase 1 N=26 Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg
Pain
Primary: AUC(0-t) — 5886; 4761 ng.h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=800 Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
Pneumococcal Infections
Primary: Concentration of Serotype-Specific IgG Antibodies — 15.26; 0.01; 3.1; 0.06 ug/ml
Phase 1 N=16 A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
Tumors
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 0; 2 Participants
Phase 1 N=52 Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Advanced Cancer
Primary: Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level — 1; 3; 0; 2 Participants
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
Phase 1 N=6 Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers
Latent Tuberculosis Infection · Tuberculosis
Primary: VAS Pain Score (Visual Analogic Scale, That Ranges From 0 to 100) to Evaluate Each Volunteer Subjective Pain Intensity at the Inoculation Point
Phase 1 N=45 Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing
Skin Graft
Primary: Complete Wound Healing — 13.9; 7.2; 5.7 Days — p=0.05
Phase 1 N=100 Phase I Pediatric FMP2.1/AS02A Trial in Mali
Plasmodium Falciparum Malaria
Primary: Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60. — 0; 0; 0; 0…
Phase 1 N=26 A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
Type 2 Diabetes Mellitus
Primary: Urinary 11-Dehydrothromboxane B2 (11-dTxB2) — 525.3; 540.8; 585.3; 625.1 pg/mg creatinine
Phase 1 N=26 A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Hypercholesterolemia
Primary: Urinary 11-dehydrothromboxane B2 (11-dTxB2) — 414.6; 371.6; 407.3; 466.1 pg/mg creatinine
Phase 1 N=95 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally
Influenza
Primary: Antibody Responses in Nasal Secretions to Influenza A/H1N1 and A/H3N2 at 14 Days After Intranasal Immunization. — 3; 3; 5; 0 Participants